LEADER 04442nam  2200709Ia 450 
001 9910145965203321
005 20230721005027.0
010   $a1-282-05799-5
010   $a9786612057991
010   $a92-4-068353-4
035   $a(CKB)1000000000718645
035   $a(EBL)420990
035   $a(OCoLC)257839542
035   $a(SSID)ssj0000166541
035   $a(PQKBManifestationID)11161933
035   $a(PQKBTitleCode)TC0000166541
035   $a(PQKBWorkID)10160926
035   $a(PQKB)11378213
035   $a(MiAaPQ)EBC420990
035   $a(Au-PeEL)EBL420990
035   $a(CaPaEBR)ebr10277793
035   $a(CaONFJC)MIL205799
035   $a(EXLCZ)991000000000718645
100   $a20081206d2008      uy             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aGuidelines for the programmatic management of drug-resistant tuberculosis$b[electronic resource] $eemergency update 2008
205   $aEmergency update.
210   $aGeneva $cWorld Health Organization, Stop TB Department$dc2008
215   $a1 online resource (270 p.)
300   $aDescription based upon print version of record.
311   $a92-4-154758-8 
320   $aIncludes bibliographical references and index.
327   $aCOVER; COPYRIGHT; CONTENTS; Acknowledgements; Abbreviations; Executive summary; Foreword to the 2008 emergency updated edition; CHAPTER 1: Background information on DR-TB; CHAPTER 2: Framework for effective control of DR-TB; CHAPTER 3: Political commitment and coordination; CHAPTER 4: Definitions:case registration, bacteriology and treatment outcomes; CHAPTER 5: Case-finding strategies; CHAPTER 6: Laboratory aspects; CHAPTER 7: Treatment strategies for MDR-TB and XDR-TB; CHAPTER 8: Mono-resistant and poly-resistant strains; CHAPTER 9: Treatment of DR-TB in special conditions and situations
327   $aCHAPTER 10: DR-TB and HIV infectionCHAPTER 11: Initial evaluation, monitoring of treatment and management of adverse effects; CHAPTER 12: Treatment delivery and community-based DR-TB support; Chapter 13: Management of patients after MDR-TB treatment failure; CHAPTER 14: Management of contacts of MDR-TB patients; CHAPTER 15: Drug resistance and infection control; CHAPTER 16: Human resources:training and staffing; CHAPTER 17: Management of second-line antituberculosis drugs; CHAPTER 18: Category IV recording and reporting system; CHAPTER 19: Managing DR-TB through patient-centred care
327   $aANNEX 1: Drug information sheetsANNEX 2: Weight-based dosing of drugs for adults; ANNEX 3: Suggestions for further reading; ANNEX 4: Legislation, human rights and patients' rights in tuberculosis prevention and control; ANNEX 5: Use of experimental drugs outside of clinical trials ("compassionate use"); ANNEX 6: Methodology; FORMS; INDEX; BACK COVER
330   $aThe emergence in 2006 of extensively drug-resistant strains of tuberculosis, especially in countries with a high prevalence of human immunodeficiency virus, are serious threats to global public health and jeopardizes efforts to effectively control the disease. These important developments and the availability of new evidence related to the diagnosis and management of drug-resistant tuberculosis have mandated an urgent update of existing guidelines. Guidelines for the programmatic management of drug-resistant tuberculosis: emergency updated edition 2008 replaces previous publications by the Wor
606   $aAntitubercular agents
606   $aComorbidity$xTreatment
606   $aHighly active antiretroviral therapy
606   $aHIV infections$xChemotherapy
606   $aMultidrug-resistant tuberculosis$xChemotherapy
606   $aMultidrug-resistant tuberculosis$xPrevention
615  0$aAntitubercular agents.
615  0$aComorbidity$xTreatment.
615  0$aHighly active antiretroviral therapy.
615  0$aHIV infections$xChemotherapy.
615  0$aMultidrug-resistant tuberculosis$xChemotherapy.
615  0$aMultidrug-resistant tuberculosis$xPrevention.
676   $a615.58
701   $aJaramillo$b Ernesto$01235886
712 02$aStop TB Initiative (World Health Organization)
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910145965203321
996   $aGuidelines for the programmatic management of drug-resistant tuberculosis$92870216
997   $aUNINA